<scp>ARF6</scp> Promotes <scp>AML</scp> Progression via Activation of <scp>PI3K</scp> / <scp>AKT</scp> / <scp>mTOR</scp> Signaling

Collectively, our findings establish ARF6 as a valuable diagnostic and prognostic marker in AML, driving disease progression through the activation of the PI3K/AKT/mTOR pathway. These insights not only enhance our understanding of AML pathology but also underscore the potential of targeting ARF6 for therapeutic intervention in AML treatment paradigms. Future research should aim at evaluating the therapeutic implications of targeting ARF6 in combination with existing treatment modalities.